Royal Bank of Canada
TRVI icon

Royal Bank of Canada’s Trevi Therapeutics TRVI Stock Holding History

Royal Bank of Canada’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$668K Buy
35,804
+3,202
+10% +$46.6K ﹤0.01% 4137
2026
Q1 		$389K Sell
32,602
-517
-2% -$5.79K ﹤0.01% 4319
2025
Q4 		$415K Sell
33,119
-135,875
-80% -$1.57M ﹤0.01% 4307
2025
Q3 		$1.55M Sell
168,994
-655,186
-79% -$4.91M ﹤0.01% 3614
2025
Q2 		$4.51M Buy
824,180
+805,082
+4,216% +$5.01M ﹤0.01% 2649
2025
Q1 		$121K Buy
19,098
+15,387
+415% +$73.4K ﹤0.01% 5096
2024
Q4 		$15K Sell
3,711
-4,560
-55% -$14.6K ﹤0.01% 6237
2024
Q3 		$28K Buy
8,271
+2,729
+49% +$8.11K ﹤0.01% 5983
2024
Q2 		$16K Buy
5,542
+4,079
+279% +$11.3K ﹤0.01% 6167
2024
Q1 		$5K Sell
1,463
-12,733
-90% -$28.4K ﹤0.01% 6465
2023
Q4 		$19K Buy
14,196
+7,208
+103% +$10.9K ﹤0.01% 6340
2023
Q3 		$15K Buy
6,988
+2,645
+61% +$5.98K ﹤0.01% 6289
2023
Q2 		$10K Buy
+4,343
New +$10.9K ﹤0.01% 6489
2022
Q4 		– Sell
-149
Closed – – 7728
2022
Q3 		$0 Buy
+149
New +$489 ﹤0.01% 7868

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Royal Bank of Canada's TRVI Position: Q2 2026 in Review

Royal Bank of Canada increased its Trevi Therapeutics (TRVI) stake by 9.8% in Q2 2026, buying an estimated $46.6K and bringing the position to 35,804 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #4137.

Royal Bank of Canada first reported a position in TRVI in Q3 2022 and has held it in 14 quarters since. The position peaked at $4.51M in Q2 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Royal Bank of Canada held 35,804 shares of Trevi Therapeutics worth $668K as of Q2 2026.
  • Royal Bank of Canada bought 3,202 Trevi Therapeutics shares in Q2 2026, an estimated $46.6K.
  • Trevi Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4137 holding.
  • Royal Bank of Canada first reported a position in Trevi Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Royal Bank of Canada's Trevi Therapeutics position peaked at $4.51M in Q2 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.